Sirtex Announces New Medical Director for U.S. Operations.
Dr. Cade joined Sirtex in 2003 after serving as a global associate at Booz Allen Hamilton in Melbourne, Australia. Previously, he held a cardiothoracic surgery teaching position at the Monash Medical Centre in Melbourne, Australia. Dr. Cade received his Bachelor of Medicine Bachelor of Surgery degree from Monash University and a Masters degree in Business Administration from the Melbourne Business School in Melbourne, Australia.
"We are very excited to have Dr. Cade join our U.S. operations," says Charles Rowland, president of Sirtex Medical. "Our mission in 2006 is to advance our training and education programs to better serve physicians who administer SIR-Spheres microspheres. Dr. Cade will also play an integral role in the development of our clinical research strategy."
Sirtex's SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors, sparing healthy liver tissue. Clinical research shows that the use of SIR-Spheres microspheres increases patient survival rates by an average of five to six months.
Approximately 55 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 60 medical centers. The minimally invasive procedure is performed on an out-patient basis with minor side effects.
SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit www.sirtex.com.